Literature DB >> 26225493

Optimization of paeonol-loaded microparticle formulation by response surface methodology.

Sha-Sha Li1,2, Guo-Feng Li2, Li Liu3, Hui Li4, Xiao Jiang3, Xue-Ling Li3, Zhi-Gang Liu3, Ting Zuo3, Li-Dong Weng3, Qiang Liu3.   

Abstract

In this study, a central composite rotatable design based on response surface methodology (RSM) was employed to design and formulate an appropriate paeonol microparticle formulation. Five levels of a three-factor, rotatable, central composite design were used to evaluate the critical formulation variables. The optimum conditions for preparing paeonol-loaded microparticles were predicted to be: polyvinyl alcohol (PVA) content (2.84%), the ratio of drug to polymer (6.88) and the stirring rate (1007.59 rpm). The optimized responses for production yield and loading efficiency were found to be 68.86% and 55.90%, respectively, and the particle size were 23.27 ± 0.76 µm and the sorting coefficient (σ) was 0.732. Furthermore, in vitro release study suggested that microparticle could be a suitable delivery system in treating skin disease for its sustained release of drug. In conclusion, RSM can be successfully used to optimize the effect of formulation variables.

Entities:  

Keywords:  Central composite rotatable design; microparticle; paeonol; particle size; response surface methodology

Mesh:

Substances:

Year:  2015        PMID: 26225493     DOI: 10.3109/02652048.2014.918664

Source DB:  PubMed          Journal:  J Microencapsul        ISSN: 0265-2048            Impact factor:   3.142


  2 in total

1.  Understanding the Effects of Associated Factors in the Development of Microsponge-Based Drug Delivery: a Statistical Quality by Design (QbD) Approach Towards Optimization.

Authors:  Shibam Karmakar; Sourav Poddar; Jasmina Khanam
Journal:  AAPS PharmSciTech       Date:  2022-09-16       Impact factor: 4.026

Review 2.  Beneficial Effects Exerted by Paeonol in the Management of Atherosclerosis.

Authors:  Li Lu; Yating Qin; Chen Chen; Xiaomei Guo
Journal:  Oxid Med Cell Longev       Date:  2018-11-07       Impact factor: 6.543

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.